Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.

  title={Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.},
  author={Michelle Roseman and Katherine Milette and Lisa A. Bero and James Coyne and Joel R Lexchin and Erick H Turner and Brett D. Thombs},
  volume={305 10},
CONTEXT Disclosure of conflicts of interest (COIs) from pharmaceutical industry study funding and author-industry financial relationships is sometimes recommended for randomized controlled trials (RCTs) published in biomedical journals. Authors of meta-analyses, however, are not required to report COIs disclosed in original reports of included RCTs. OBJECTIVE To investigate whether meta-analyses of pharmacological treatments published in high-impact biomedical journals report COIs disclosed… 

Tables from this paper

Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009

Investigate the extent to which pharmaceutical industry funding and author-industry FCOIs and employment from included drug trials are reported in meta-analyses published in high-impact journals and compare current reporting with results from 2009 to find reporting of drug trial sponsorship and author FCOis has increased but is still suboptimal.

Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study

Reporting of trial funding sources, trial author–industry financial ties and trial author-industry employment in Cochrane meta-analyses has improved since 2010 and is higher than in non-Cochrane meta -analyses.

Authorial Conflicts of Interest and Sponsorship in Systematic Reviews and Meta-Analyses on Psoriasis

This study identifies conflicts of interest and industry-author relationships in systematic reviews on psoriasis treatment and provides examples of how specific industry ties can influence systematic reviews and recommendations for reporting.

Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors

Evidence on common instances of conflict of interest (COI) in research publications from general and specialized fields of biomedicine is overviewed and joint efforts of authors, peer reviewers, and editors are considered as a foundation for appropriately defining and disclosing potential COIs.

Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study

Most Cochrane reviews of drug trials published in 2010 did not provide information on trial funding sources or trial author-industry financial ties or employment, and location of reporting was inconsistent across reviews.

Disclosures of Conflicts of Interest in Psychiatric Review Articles

Efforts to screen out authors with significant financial relationships pertaining to the topic under review may be more effective than are disclosures in protecting the integrity of the medical literature.

Industry sponsorship and research outcome.

The analyses suggest the existence of an industry bias that cannot be explained by standard 'Risk of bias' assessments.

Conflict of interest reporting in dentistry meta-analyses: A systematic review

Although few conflicts appear to exist, the field of dentistry should continue to ensure that best evidence reports provide clear and transparent reporting of potential conflicts of interest in academic journals.

Identifying competing interest disclosures in systematic reviews of surgical interventions and devices: a cross-sectional survey

In surgical SRs, there is a high percentage of competing interest disclosures but without detailed information, and the identification and statement of competing interests with a detailed description, particularly the non-financial ones, needs improvement.



Scope and impact of financial conflicts of interest in biomedical research: a systematic review.

Original, quantitative studies on the extent, impact, and management of financial conflicts of interest in biomedical research are reviewed to show a statistically significant association between industry sponsorship and pro-industry conclusions.

The association between funding by commercial interests and study outcome in randomized controlled drug trials.

An association was found between the source of study support and the published outcome of randomized controlled drug trials in general interest medical journals.

Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

Any attempt to recommend a specific selective serotonin reuptake inhibitor from the publicly available data only is likely to be based on biased evidence.

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

Investigating whether funding of drug studies by the pharmaceutical industry is associated with outcomes that are favourable to the funder and whether the methods of trials funded by pharmaceutical companies differ from the methods in trials with other sources of support found systematic bias favours products which are made by the company funding the research.

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

Conclusions in trials funded by for-profit organizations may be more positive due to biased interpretation of trial results, and readers should carefully evaluate whether conclusions in randomized trials are supported by data.

Factors Associated with Findings of Published Trials of Drug–Drug Comparisons: Why Some Statins Appear More Efficacious than Others

Associations between research funding source, study design characteristics aimed at reducing bias, and other factors that potentially influence results and conclusions in randomized controlled trials (RCTs) of statin–drug comparisons are examined.

Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review

Findings do not necessarily indicate a causal link between the position taken on the cardiac risk of rosiglitazone in patients with diabetes and the authors’ financial conflicts of interest, but underscore the need for further changes in disclosure procedures in order for the scientific record to be trusted.

Relationships between authors of clinical practice guidelines and the pharmaceutical industry.

There appears to be considerable interaction between CPG authors and the pharmaceutical industry, and the need for appropriate disclosure of financial conflicts of interest for authors of CPGs and a formal process for discussing these conflicts prior to CPG development is highlighted.

Relationship between conflicts of interest and research results

COI is widespread among the authors of published manuscripts and these authors are more likely to present positive findings, and a strong association between positive results and COI (ICMJE definition) is observed.

Selective publication of antidepressant trials and its influence on apparent efficacy.

A systematic literature search found that among 74 FDA-registered studies, 31%, accounting for 3449 study participants, were not published, and the increase in effect size ranged from 11 to 69% for individual drugs and was 32% overall.